Navigation Links
Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program

SAN DIEGO, June 16 /PRNewswire/ -- Victory Pharma, Inc., a specialty pharmaceutical company focused on pain and related areas of medicine, today announced the recent initiation of the first of two clinical studies for MGX006 antiemetic pivotal clinical program.

"Data from the Phase 2 studies confirming pivotal formulation selection and end-of-phase 2 discussions with the FDA regarding the registration study designs provides confidence that MGX006 will move rapidly through pivotal development," explained Dr. Shawn Scranton, Vice President of Scientific Operations. "Victory is pleased with the results to date and is confident that MGX006 will provide an important therapeutic alternative for patients suffering from emesis of various etiologies," continued Dr. Scranton.

"MGX006 represents a key milestone for Victory," stated Matthew Heck, President and CEO. "This novel approach to antiemetic therapy is the company's first internally developed pipeline product, demonstrating our commitment to developing solutions for unmet medical needs. We look forward to marketing MGX006 in the U.S. with our specialty sales force."

About MGX006

MGX006 utilizes a proprietary formulation applied to a previously approved antiemetic agent. The formulation was created utilizing patented technology through a partnership and has properties that make MGX006 ideally suited for the treatment of nausea and vomiting.

About Victory Pharma, Inc.

Victory Pharma, Inc. is a private San Diego based specialty pharmaceutical company focused on acquiring, marketing and developing proprietary pain and related products. Victory markets its existing pain products through its field sales force headquartered in Cary, NC, and is currently developing several products in pain and pain complementary markets. Further information regarding Victory is available at

SOURCE Victory Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
(Date:11/26/2015)... the Netherlands , November 26, 2015 ... A new combination approach blends immunotherapy with ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic ... the Netherlands has found that immunotherapy can ...
(Date:11/26/2015)... --> --> Juntendo University ... contrast weighting of MRI for patients with Multiple Sclerosis ... agreement with SyntheticMR in order to use SyMRI in clinical ... to generate multiple contrast images from a single scan and ... making it possible to both fine tune images and recreate ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, ... Table 1-1 ). More than 3.7 billion people under the age of 50 – ... according to WHO's first global estimates of HSV-1 infection . , "The data shocks ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
(Date:11/27/2015)... MINNEAPOLIS, Minn. (PRWEB) , ... November 27, 2015 ... ... you start failing. Secura Consultants has prided itself for not only fulfilling the ... best income protection solutions at an affordable price and providing top-tier customer service. ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... CBD ... Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography ... CAAHEP accredited colleges, as only one of twelve colleges and universities in the state ...
(Date:11/27/2015)... Rosa, CA (PRWEB) , ... November 27, 2015 , ... ... Northern California Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at ... meeting. They observed that both STEMI and Sepsis conditions present in similar ways and ...
Breaking Medicine News(10 mins):